PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney

被引:27
作者
Vranic, Semir
Bilalovic, Nurija
Lee, Lisa M. J.
Kruslin, Bozo
Litleberg, Stan L.
Gatatica, Zoran [1 ]
机构
[1] Creighton Univ, Med Ctr, Dept Pathol, Omaha, NE 68131 USA
[2] Univ Sarajevo, Ctr Clin, Dept Pathol, Sarajevo 71000, Bosnia & Herceg
[3] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Ljudevit Jurak Dept Pathol, Zagreb 10000, Croatia
[4] Transgenom Inc, Transgenom Labs, Dept Translat & Clin Res, Omaha, NE 68164 USA
关键词
adenoid cystic carcinoma; breast; mTOR; PIK3CA; PTEN; CANCER; RESISTANCE; KIT;
D O I
10.1016/j.humpath.2007.03.021
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Adenoid cystic carcinoma (ACC) of the breast rarely metastasizes and has been associated with excellent prognosis. We describe a patient with renal metastasis of primary breast ACC 5 years after the mastectomy. A detailed molecular genetic analysis of the primary and metastatic tumors demonstrated somatic mutations in 2 well-known cancer genes associated with regulation of PI3K/AKT signaling pathway: (1) PIK3CA, which encodes the catalytic g subunit of the phosphomositide-3-kinase, and (2) PTEN, which encodes phosphatase and tensin homolog. The mutation identified in PIK3CA (Exl+169 A > C) predicts an amino acid change from isoleucine to methionine at codon 31 (13 1 M) and resides in the p85-binding domain of exon 1. The mutation identified in PTEN (IVS4-3 C > T) resides in intron 4 near the splice acceptor site of exon 5 and was associated with an aberrant PTEN transcript lacking exon 5, which is necessary for protein tyrosine phosphatase function and tumor suppressor properties of PTEN. Increased promoter methylation of PTEN was present in renal metastasis, coinciding with the decrease in the level of normal PTEN transcript. These coexistent mutations/epigenetic inactivations in PI3K/AKT pathway may be responsible for the unusually aggressive course of ACC. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1425 / 1431
页数:7
相关论文
共 50 条
  • [1] Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
    Razis, E.
    Bobos, M.
    Kotoula, V.
    Eleftheraki, A. G.
    Kalofonos, H. P.
    Pavlakis, K.
    Papakostas, P.
    Aravantinos, G.
    Rigakos, G.
    Efstratiou, I.
    Petraki, K.
    Bafaloukos, D.
    Kostopoulos, I.
    Pectasides, D.
    Kalogeras, K. T.
    Skarlos, D.
    Fountzilas, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 447 - 456
  • [2] The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma
    Adderley, Helen
    Rack, Samuel
    Hapuarachi, Brindley
    Feeney, Laura
    Morgan, David
    Hussell, Tracy
    Wallace, Andrew J.
    Betts, Guy
    Hodgson, Clare
    Harrington, Kevin
    Metcalf, Robert
    ORAL ONCOLOGY, 2021, 113
  • [3] PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast
    Li, Hua
    Zhu, Rong
    Wang, Lei
    Zhu, Tengfang
    Li, Qiong
    Chen, Qi
    Wang, Hong
    Zhu, Hongguang
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2010, 88 (01) : 150 - 155
  • [4] Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
    E. Razis
    M. Bobos
    V. Kotoula
    A. G. Eleftheraki
    H. P. Kalofonos
    K. Pavlakis
    P. Papakostas
    G. Aravantinos
    G. Rigakos
    I. Efstratiou
    K. Petraki
    D. Bafaloukos
    I. Kostopoulos
    D. Pectasides
    K. T. Kalogeras
    D. Skarlos
    G. Fountzilas
    Breast Cancer Research and Treatment, 2011, 128 : 447 - 456
  • [5] PIK3CA Mutations and PTEN Loss in Salivary Duct Carcinomas
    Griffith, Christopher C.
    Seethala, Raja R.
    Luvison, Alyssa
    Miller, Megan
    Chiosea, Simion I.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (08) : 1201 - 1207
  • [6] Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
    Palimaru, Irina
    Brugmann, Anja
    Wium-Andersen, Marie Kim
    Nexo, Ebba
    Sorensen, Boe Sandahl
    SPRINGERPLUS, 2013, 2 : 1 - 7
  • [7] PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer
    Agahozo, Marie Colombe
    Sieuwerts, Anieta M.
    Doebar, S. Charlane
    Verhoef, Esther, I
    Beaufort, Corine M.
    Ruigrok-Ritstier, Kirsten
    de Weerd, Vanja
    Sleddens, Hein F. B. M.
    Dinjens, Winand N. M.
    Martens, John W. M.
    van Deurzen, Carolien H. M.
    ENDOCRINE-RELATED CANCER, 2019, 26 (05) : 471 - 482
  • [8] Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
    Rugo, Hope S.
    Raskina, Kira
    Schrock, Alexa B.
    Madison, Russell W.
    Graf, Ryon P.
    Sokol, Ethan S.
    Sivakumar, Smruthy
    Lee, Jessica K.
    Fisher, Virginia
    Oxnard, Geoffrey R.
    Tukachinsky, Hanna
    CLINICAL CANCER RESEARCH, 2023, 29 (06) : 1056 - 1067
  • [9] PIK3CA mutations in cutaneous squamous cell carcinoma
    Kusaba, Yudo
    Kajihara, Ikko
    Sakamoto, Ryoko
    Maeda-Otsuka, Saki
    -Kanazawa, Saori Yamada
    Sawamura, Soichiro
    Makino, Katsunari
    Aoi, Jun
    Masuguchi, Shinichi
    Fukushima, Satoshi
    INTRACTABLE & RARE DISEASES RESEARCH, 2023, 12 (03) : 206 - 207
  • [10] PIK3CA Mutations in In situ and Invasive Breast Carcinomas
    Miron, Alexander
    Varadi, Maria
    Carrasco, Daniel
    Li, Hailun
    Luongo, Lauren
    Kim, Hee Jung
    Park, So Yeon
    Cho, Eun Yoon
    Lewis, Gretchen
    Kehoe, Sarah
    Iglehart, J. Dirk
    Dillon, Deborah
    Allred, D. Craig
    Macconaill, Laura
    Gelman, Rebecca
    Polyak, Kornelia
    CANCER RESEARCH, 2010, 70 (14) : 5674 - 5678